Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications assessment pro label claims granted fda compared ema 2006���2010
… Webinar: Characteristics of Recent PRO Labeling by the FDA and EMA for Oncology Drugs Share on: … will be highlighted to help sponsors pursuing labeling claims from both agencies. Learning objectives • What are the main characteristics of the labels granted by the FDA and the EMA for PRO-related endpoints, …
… acceptable to the FDA following the release of the FDA’s PRO Guidance. To support these efforts, we have developed … to FDA meetings in support of their proposed labeling claims. Our experts, particularly those based in Europe, also … negotiate acceptability of COA-based endpoints for use in label claims, as well as guiding industry clients through the …
… RTI-HS Webinar - Lessons Learned From a Review of FDA PRO Labeling Share on: December 12, 2016 Image Click to … to drug manufacturers. The Patient-Centered Outcomes Assessment team at RTI Health Solutions has analyzed FDA PRO …
… for pharmaceutical clients at the request of the US FDA, EMA, and other national agencies in North America, Europe, … covered by electronic medical records, administrative claims, and registries for several decades. For each project …
… Patient-Centered Outcomes Assessment Whether your goal is to support product claims, facilitate market access, or improve … assessments (COAs), including patient-reported outcome (PRO), observer-reported outcome (ObsRO), clinician-reported …
… Utility Assessment Health utility estimates provide a representation … Develop a health preference index from a disease-specific PRO instrument - Conduct health preference assessments using … such as NICE, SMC, CDR, and PBAC), value messaging , and publications A Team Approach Let our multidisciplinary team …
… The agency encourages modifying and adapting existing PRO instruments, where feasible, rather than creating new … of clinical research (e.g., electronic health records, claims and billing activities, product and disease … about the amount of change that is clinically meaningful. Assessment of a PRO instrument as “fit for purpose” is …
… FDA Rare Disease Day 2024 Virtual Public Meeting Share on: … Romano, M.S., Vice President of Patient-Centered Outcomes Assessment at RTI Health Solutions, will be presenting at the … on the FDA-sponsored study to adapt an in-clinic outcome assessment tool for ALS to remote-use at home. Panel 3: …
… and evaluated the psychometric properties of hundreds of PRO instruments and other types of COAs to assess health … questions, and response scales Translatability assessment and cross-cultural adaptation Migration to … including regulatory submissions, reports, and publications Support to secure regulatory acceptability of …
… The agency encourages modifying and adapting existing PRO instruments, where feasible, rather than creating new … of clinical research (e.g., electronic health records, claims and billing activities, product and disease … about the amount of change that is clinically meaningful. Assessment of a PRO instrument as “fit for purpose” is …